PRMT5 and colorectal cancer: Furthermore, in vivo functional experiments revealed that overexpression of PRTM5 promoted colorectal cancer liver metastasis (Figure 5E), whereas the overexpression of the methyltransferase‐inactive PRMT5 R368A mutant did not affect liver metastasis, and the ability of PRMT5 to promote metastasis was reversed by rapamycin treatment (Figure 5E).